FDA approves generic version of Diovan for Hypertension-Ranbaxy
The FDA has approved Ranbaxy Laboratories Ltd's generic version of Diovan (valsartan) for treatment of Hypertension. The patent rights to Diovan in the United States expired for Novartis at the end of 2012 but the company has avoided generic competition because of multiple quality control problems at Ranbaxy plants in the US that prevented the company from exercising its right to become the first generic version of the drug. The drug will now be launched as soon as sufficient supplies are manufactured to meet the needs of the market.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins